FindTrial
Sign In

proton pump inhibitor and H2 antagonist in the prevention of antiplatelet drugs associated upper gastrointestinal bleeding and rebleeding

proton pump inhibitor and H2 antagonist in the prevention of antiplatelet drugs associated upper gastr

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-14005512
Enrollment
Unknown
Registered
2014-09-16
Start date
2013-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

upper gastrointestinal bleeding

Interventions

PPI:rabeprazole vs control

Sponsors

Department of Gastroenterology and Hepatology, the Chinese PLA General Hospital, Beijing 100853, China.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. the patients who need dual-antiplatelet therapy of aspirin and clopidogrel; 2. age from 18-75 years old; 3. patients who signed informed consents.

Exclusion criteria

Exclusion criteria: the patients who suffered from esophagitis, esophageal gastric varices;stomach operation history;longterm use of PPI,H2RA or misoprostol; anticoagulant and fibrinolytic therapy recently;pregnancy or breast-feeding women;with other serious diseases including liver, kidney, cardiovascular disease and malignant tumor; mental illness or severe neurosis; unable to express subjective symptoms.

Design outcomes

Primary

MeasureTime frame
upper gastrointestinal bleeding;—

Secondary

MeasureTime frame
cardiovascular effects;—

Countries

China

Contacts

Public ContactYang Yun-sheng
sunny301ddc@126.com+86 13910767280

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026